ライフサイエンスコーパス: tumor-bearing

1 umor growth in an EZH2-dependent manner, and tumors bearing a non-GNA-interacting C668S-EZH2 mutation

2 (MAPK) kinase (MEK) can induce regression of tumors bearing activating mutations in the Ras pathway b

3 d with (64)Cu, and administered to normal or tumor-bearing aged, female, retired breeder Sprague-Dawl

4 altered novel object investigation for both tumor-bearing and -resected mice relative to surgical co

5 r reversed (C3) in the respective tissues of tumor-bearing and -resected mice.

6 Bone marrow and splenic cells extracted from tumor-bearing and control mice (n= 3/group) were coincub

7 sing (18)F-FDG was successfully performed on tumor-bearing and non-tumor-bearing mice, as well as on

8 Recent discoveries using tumor bearing animal models have eluded to the autonomic

9 cryosectioning and fluorescence imaging of 1 tumor-bearing animal as well as PSMA immunohistochemistr

10 line uptake of (18)F-AH113804, determined in tumor-bearing animals after 10 d, was approximately 2-fo

11 early as 6 d after surgery in the recurrent tumor-bearing animals and exhibited significantly higher

12 Quantitative analysis of living tumor-bearing animals and fresh excised human breast tis

13 odistribution and in vivo PET imaging in non-tumor-bearing animals as well as in KB-3-1 and COLO-205

14 en leukemia models and prolonged survival of tumor-bearing animals by accelerating apoptosis of leuke

15 Tumor-bearing animals, while exhibiting increased angiog

16 and 600-fold lower as compared to untreated tumor-bearing animals.

17 gh-affinity CD8 T cells prolongs survival of tumor-bearing animals.

18 significantly undersampled imaging data from tumor-bearing animals.

19 although the nonloading group increased the tumor bearing as well as expression of IL-8 and matrix m

20 Non-tumor-bearing BALB/c mice were tested for maximum tolera

21 In tumor-bearing Balb/c nude mice, conjugate 1 preferential

22 Specifically, 3D models of tumor-bearing bone segments were constructed by using co

23 e implants in orthotopic, syngeneic ID8-VEGF tumor-bearing C57BL/6 mice.

24 es were performed using CD-1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mic

25 mpared with that seen in WT littermates, but tumor-bearing CLEC14A-KO mice died sooner.

26 r abnormalities and enhanced the survival of tumor-bearing CLEC14A-KO mice.

27 aneous/peritoneal fat depots compared to non-tumor bearing control mice.

28 126, miR-146a, and miR-125b) compared to non tumor-bearing counterparts.

29 cal trials containing >=2 arms and involving tumor-bearing dogs.

30 Tumor bearing HF control mice showed a significant incre

31 uced by experimenter-induced movement of the tumor-bearing hindlimb with a context produces condition

32 ncluding IL6, IL17, MCP-1, and GM-CSF in the tumor-bearing host, and persisted as memory cells.

33 ntially immunosuppressive environment of the tumor-bearing host.

34 ntitumor immunity which stays dormant in the tumor-bearing host.

35 upon the degree of adrenergic stress in the tumor-bearing host.

36 DCs in tumor-bearing hosts accumulate lipid bodies (LB) contain

37 Furthermore, reovirus administration in tumor-bearing hosts drives time-dependent recruitment of

38 oup of immature myeloid cells that expand in tumor-bearing hosts in response to soluble factors produ

39 We hypothesized that NO producing MDSC in tumor-bearing hosts would inhibit DC antigen presentatio

40 these effects reduced mMDSC accumulation in tumor-bearing hosts, limiting the outgrowth of KRas-driv

41 DSCs from tumor-bearing mice compared to non-tumor-bearing hosts.

42 cost of memory differentiation in wild-type tumor-bearing hosts.

43 activity is reduced in peripheral tissues of tumor-bearing hosts.

44 ells, in various tissue compartments of oral tumor-bearing hu-BLT mice in response to immunotherapy b

45 treatment with CEA-TCB/CEA-4-1BBL in MKN-45 tumor-bearing humanized mice correlated with intratumora

46 wed different therapeutic responses in E.G-7 tumor-bearing immune-competent mice, in which they were

47 In ovalbumin (OVA)-expressing E.G-7 tumor-bearing immune-deficient mice, intravenously injec

48 In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells w

49 s (MDSC) contribute to immune suppression in tumor-bearing individuals and are a major obstacle to ef

50 a steady-state level of circulating MDSC in tumor-bearing individuals.

51 rmacologic inhibition of the PI3K pathway in tumor-bearing Kit(V558Delta/+) mice with the dual PI3K/m

52 Younger, non-tumor-bearing KPC mice that show uptake of (111)In-anti-

53 an be used to ablate target tissues in a non-tumor-bearing large-animal model while selectively spari

54 breast adenocarcinoma tumors had normal non-tumor-bearing liver treated with RFA (70 degrees C x 5 m

55 ystemically delivering TTK siRNAs to already tumor-bearing liver, limits intrahepatic spread of liver

56 ore, fractionated radiation delivered to one tumor-bearing lung synergizes with inhaled NP-cGAMP, eli

57 and lymphocytic infiltration of inflamed or tumor-bearing lung.

58 Tumor-bearing lungs of 5-LO-KO had decreased numbers of

59 distribution studies were conducted on LNCaP tumor-bearing male CB-17 SCID mice.

60 i-CTLA-4 siRNA-loaded NPs into CT26 and 4 T1 tumor -bearing mice led to the downregulation of CTLA-4

61 Moreover, while the treatment of tumor -bearing mice with DC vaccine had mild therapeutic

62 so detected in tumor-draining lymph nodes of tumor bearing mice and in biopsies of patients with glio

63 r models develop overt metastasis while EMT6-tumor bearing mice clear DTCs shed from primary tumors a

64 eated and abscopal sites achieved in 8 of 11 tumor bearing mice over 100 days.

65 Treatment of WAP-Int3 tumor bearing mice with an IKK inhibitor resulted in tum

66 Treatment of tumor bearing mice with systemic administration of IL-12

67 r intravenous treatment of RDLPNPs into Hela tumor bearing mice, fluorescent (from DiR) and enhanced

68 was demonstrated in D54 glioma and A549 lung tumor bearing mice.

69 of drug resistance was studied in pancreatic tumor bearing mice.

70 Remarkably, in C26-tumor-bearing mice (+)-JQ1 administration dramatically p

71 py was determined by longitudinal imaging of tumor-bearing mice (MC38 and A9F1) undergoing 2 types of

72 f dasatinib and extended the survival of PPK tumor-bearing mice (mutant TP53, mutant PDGFRA, H3K27M).

73 umumab- versus IgG1-treated COLO205 and HT29 tumor-bearing mice (P = 0.104 and 0.779, respectively) a

74 ssing VEGF-B or control vector to normal and tumor-bearing mice 1 wk before DOX treatment, using dose

75 Short-term fasting protects tumor-bearing mice against the toxic effects of chemothe

76 or-infiltrating PD-L1(+) cells isolated from tumor-bearing mice also exerted morphology of tumor-asso

77 Moreover, MEKi treatment of tumor-bearing mice also showed strong immune-mediated an

78 ite elevated plasma levels of VEGFA in fs120 tumor-bearing mice and a dependence on VEGF receptor 1 a

79 ased efficacy of PD-1/PD-L1 blockade in both tumor-bearing mice and clinical cancer patients.

80 eloid-derived suppressor cells in spleens of tumor-bearing mice and ex vivo.

81 e fluorescence guidance were investigated in tumor-bearing mice and healthy pigs.

82 IL6 was abundantly expressed in MDSCs in tumor-bearing mice and patients with human colorectal ca

83 a signaling was increased in tumor-MDSC from tumor-bearing mice and patients with ovarian cancer.

84 h 3P10 reverses excessive lipid oxidation in tumor-bearing mice and prevents cancer cachexia, even un

85 both significantly increased the survival of tumor-bearing mice and showed promising antitumor effica

86 in tumor cells induced complete responses in tumor-bearing mice and supported memory development in t

87 R5 ligand interactions increased survival of tumor-bearing mice and was associated with reduced migra

88 did not affect circulating levels of MDSC in tumor-bearing mice because the decreased apoptotic rate

89 NETs were detected in the omentum of ovarian tumor-bearing mice before metastasis and of women with e

90 -PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in

91 tudy, we demonstrate that IL-2c treatment in tumor-bearing mice can enhance NK cell and tumor-specifi

92 sion was significantly reduced in MDSCs from tumor-bearing mice compared to non-tumor-bearing hosts.

93 greater antitumor efficacy in EG.7 and TC-1 tumor-bearing mice compared to the control (p < 0.01).

94 ne (ADMA) and N(G)-monomethyl-l-arginine, in tumor-bearing mice compared with control mice.

95 Studies conducted in tumor-bearing mice confirmed the deleterious effect of r

96 We found that tumor-bearing mice deficient in the chemokine receptor C

97 Administration of CD5-2 in tumor-bearing mice enhanced expression of VE-cadherin in

98 Dendritic cells (DCs) from NK cell-depleted tumor-bearing mice exhibited a more mature phenotype.

99 After 21 days, tumor-bearing mice exhibited reduced body and muscle mas

100 that the pan-BET inhibitor (+)-JQ1 protects tumor-bearing mice from body weight loss and muscle and

101 ut not PCAF/GCN5 inhibitor CPTH6, spared LLC tumor-bearing mice from muscle wasting.

102 In addition, tumor-bearing mice given T-cell-depleted allo-BMT (allo-

103 recipient cells, and circulating EC-EVs from tumor-bearing mice harbor elevated levels of specific mi

104 n occupancy and gene expression in young and tumor-bearing mice identified a set of shared targets fo

105 Tumor-bearing mice implanted with A431-GFP, MDAMB468-GFP

106 siRNA-mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cance

107 plore the function of salivary exosomes from tumor-bearing mice in immune surveillance.

108 c model and improved the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model.

109 rpolarized [1,3-(13)C(2)]AcAc in healthy and tumor-bearing mice in vivo.

110 reased MDSC accumulation and tumor growth in tumor-bearing mice in vivo.

111 Non-invasive PET scans were acquired in tumor-bearing mice injected with (89)Zr-Df-ALT-836.

112 ransfer of monocytes into anti-PD-L1-treated tumor-bearing mice led to macrophage differentiation int

113 at doxorubicin (DOX) treatment of 4T1 breast tumor-bearing mice led to the induction of IL-13R(+)miR-

114 generated by treating HER2(+)/PIK3CA(H1047R) tumor-bearing mice long term with the drug combination.

115 tested in cynomolgus monkeys and pancreatic tumor-bearing mice models, respectively.

116 Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitu

117 tinib at a low dose (0.5 mg/kg/day, i.p.) in tumor-bearing mice not only alleviated muscle wasting, b

118 h increased monoclonal (M) protein (g/dL) in tumor-bearing mice over time (3.29 +/- 0.58 at week 0 an

119 Tumor-bearing mice received 2 intravenous injections of

120 sed in multiple brain regions of LPS-treated tumor-bearing mice relative to LPS-treated controls; tum

121 Anti-PD-L1 treatment of tumor-bearing mice results in cessation of tumor growth

122 Biodistribution studies in LNCaP tumor-bearing mice revealed high tumor uptake, sufficien

123 positive PC-3 PIP and PSMA-negative PC-3 flu tumor-bearing mice revealed that (86)Y- 4-6: had high si

124 ing lymph nodes of IL-12 plus GM-CSF-treated tumor-bearing mice revealed that whereas IFN-gamma induc

125 Biodistribution studies using HT29 tumor-bearing mice showed highest tumor uptake for [(68)

126 Testing in tumor-bearing mice showed that PTX-NCs treated with Plur

127 stration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but

128 esultant FA-3DNA-siHuR conjugates to ovarian tumor-bearing mice suppressed tumor growth and ascites d

129 We demonstrate that glutamine blockade in tumor-bearing mice suppresses oxidative and glycolytic m

130 hat SGG colonization is 1,000-fold higher in tumor-bearing mice than in normal mice.

131 We report that in tumor-bearing mice the macrophage colony-stimulating fac

132 logy model of VEGF transport and kinetics in tumor-bearing mice to include a tumor compartment whose

133 l for a productive CD8(+) T cell response in tumor-bearing mice treated with anti-PD-1 but were not r

134 55.6% of tumor-bearing mice treated with MHIRE were tumor-free, w

135 urvival/proliferation, and survival in brain tumor-bearing mice treated with PT2385 alone and in comb

136 Longitudinal monitoring of MC38 tumor-bearing mice undergoing anti-PD-1 treatment reveal

137 Methods: A549 tumor-bearing mice underwent a (18)F-flortanidazole PET/

138 CuSarTATE in AR42J (rat pancreatic exocrine) tumor-bearing mice was compared with (177)Lu-LuTATE.

139 hematopoiesis and myeloid differentiation in tumor-bearing mice was induced by TNFalpha, which was ma

140 percentage injected dose per gram) in LNCaP tumor-bearing mice was observed.

141 claudin-low tumors, and Tregs isolated from tumor-bearing mice were able to suppress effector T cell

142 AR42J tumor-bearing mice were dynamically scanned 0-1 h after

143 When tumor-bearing mice were given hNIS- and hSSR2-containing

144 Methods: Tumor-bearing mice were imaged with small-animal PET/CT

145 For CL-activated tagging in vivo, tumor-bearing mice were injected first with (90)Y-DOTA-R

146 hment of this preclinical model, a cohort of tumor-bearing mice were injected with the chemotherapeut

147 Tumor-bearing mice were randomized into trebananib or ve

148 HCC cells in vitro.Materials and MethodsHCC tumor-bearing mice were randomized to neoadjuvant PI3K/m

149 Tumor-bearing mice were treated with anti-Ang2 antibodie

150 Tumor-bearing mice were treated with JQ1 (50 mg/kg daily

151 triple-negative breast cancer model, whereby tumor-bearing mice were treated with pan-TAM kinase inhi

152 y, in the murine model, approximately 40% of tumor-bearing mice were tumor-free after a single treatm

153 d tumor growth and prolonged the survival of tumor-bearing mice when given as monotherapy.

154 We demonstrate that treatment of tumor-bearing mice with a blocking anti-M-CSFR monoclona

155 In parallel, tumor-bearing mice with access to running wheels showed

156 Treatment of tumor-bearing mice with anti-MerTK antibody stimulated T

157 T cell responses upon systemic treatment of tumor-bearing mice with antimalarial drugs.

158 eting platelet function pharmacologically in tumor-bearing mice with aspirin and clopidogrel in combi

159 1 immunity in CNS tissues, we infected GL261 tumor-bearing mice with attenuated rabies virus (RABV).

160 istribution studies were performed in LS174T tumor-bearing mice with AVP04-07-TCO(n) (where n indicat

161 Tumor-bearing mice with CCL22 deficiency showed prolonge

162 Treatment of BNC tumor-bearing mice with cisplatin and pemetrexed, the cu

163 Treatment of orthotopic pancreatic tumor-bearing mice with gemcitabine alone or in combinat

164 Furthermore, treatment of E.G7-OVA tumor-bearing mice with Lp/OVA/StII significantly reduce

165 ncing in MCL cells and prolonged survival of tumor-bearing mice with no observed adverse effects.

166 s mechanism of action is preserved, to treat tumor-bearing mice with otherwise lethal levels of chemo

167 Similarly, treatment of ovarian tumor-bearing mice with PD-1 blocking antibody resulted

168 Treatment of tumor-bearing mice with PT2385 caused dramatic tumor reg

169 After 35-days, the peritoneum of tumor-bearing mice with PTX-nanotextiles was completely

170 mor model system, a single s.c. injection of tumor-bearing mice with R-DOTAP plus human papillomaviru

171 y decreased tumor weight and splenomegaly in tumor-bearing mice with reduced accumulation of polymorp

172 ine liver metastasis (LM) model, by treating tumor-bearing mice with STAT3 inhibitors (STATTIC or BBI

173 P78-regulated metabolite changes by treating tumor-bearing mice with tamoxifen and/or linoleic acid.

174 Treatment of HCC-PDX xenograft tumor-bearing mice with the c-Kit inhibitor imatinib sig

175 tumor growth through apoptosis in NSCLC H460 tumor-bearing mice without nephrotoxicity.

176 omparison with controls after injection into tumor-bearing mice, and promoted DC maturation, leading

177 cessfully performed on tumor-bearing and non-tumor-bearing mice, as well as on controls bearing sites

178 In U87MG tumor-bearing mice, both tracers showed similar tumor up

179 foundly block naive CD8(+) T cell priming in tumor-bearing mice, but actually increased the number of

180 show that upon systemic administration into tumor-bearing mice, CRV selectively homes to tumors, ext

181 s, or therapeutic inhibition of Ampkalpha in tumor-bearing mice, delayed tumor growth, inhibited the

182 In tumor-bearing mice, elevated iNOS expression is a hallma

183 sfer of granulocytic-MDSCs isolated from 4T1 tumor-bearing mice, induce metastasis by suppressing CD8

184 In tumor-bearing mice, pharmacologic inhibition of DNMT wit

185 For single Raji tumor-bearing mice, pretargeting with CD20-specific FP s

186 e prolonged survival but did not cure HDLM-2 tumor-bearing mice, whereas BV combined with ruxolitinib

187 D-1-expressing cells extends the survival of tumor-bearing mice, whereas free drugs have no effect at

188 o(LA)8-PTX induced tumor regression in A549 tumor-bearing mice, whereas PTX delayed tumor growth.

189 high-dimensional analysis of immune cells in tumor-bearing mice, which eliminates gating biases and i

190 intigraphy and organ distribution studies in tumor-bearing mice.

191 tribution experiments were performed with KB tumor-bearing mice.

192 f the UPR, ameliorates muscle wasting in LLC tumor-bearing mice.

193 of skeletal muscle mass and strength in LLC tumor-bearing mice.

194 ent with 5-FU increased plasma OPN levels in tumor-bearing mice.

195 bution studies were performed on HT-1080-FAP tumor-bearing mice.

196 eases muscle wasting in Lewis lung carcinoma tumor-bearing mice.

197 effects in chemotherapy and immunotherapy in tumor-bearing mice.

198 dual dormant myeloma cells from the bones of tumor-bearing mice.

199 maging and PDT was subsequently performed in tumor-bearing mice.

200 d distant tumors, prolonging the survival of tumor-bearing mice.

201 T cell cytotoxicity and extends survival of tumor-bearing mice.

202 teristics were evaluated in normal and DLD-1 tumor-bearing mice.

203 ounds demonstrated increased tumor uptake in tumor-bearing mice.

204 er efficacy of cisplatin and radiotherapy in tumor-bearing mice.

205 significantly prolongs the survival of brain tumor-bearing mice.

206 tic Ccl2 reduction prolonged the survival of tumor-bearing mice.

207 TX014 on MDSC-mediated T-cell suppression in tumor-bearing mice.

208 d significantly extended the survival of 4T1 tumor-bearing mice.

209 oma growth and prolonged the survival of the tumor-bearing mice.

210 n vitro and in the plasma and lungs of fs120 tumor-bearing mice.

211 /group) was performed in wild-type and MM1.S tumor-bearing mice.

212 rowth inhibition and extends the survival of tumor-bearing mice.

213 also necessary for effective PD-1 therapy in tumor-bearing mice.

214 udies were performed in both B16F10 and A375 tumor-bearing mice.

215 while maintaining the antitumor efficacy in tumor-bearing mice.

216 improved anti-tumor efficacy in vivo in 4T1 tumor-bearing mice.

217 are greatly expanded in cancer patients and tumor-bearing mice.

218 uppressor cells in early metastatic sites of tumor-bearing mice.

219 gonal click reaction in cell cultures and in tumor-bearing mice.

220 mation compared with wildtype littermates in tumor-bearing mice.

221 ice and by competitive blocking in wild-type tumor-bearing mice.

222 -MDSCs, with reduced tumor burden in 4T1-Neu tumor-bearing mice.

223 opoietic stem and progenitor cells (HSPC) in tumor-bearing mice.

224 metabolites cycling exclusively in livers of tumor-bearing mice.

225 icant elevation of circulating L-selectin in tumor-bearing mice.

226 icacy of PLD and conventional doxorubicin in tumor-bearing mice.

227 2-MZP B cells possess regulatory activity in tumor-bearing mice.

228 argeting correlated with reduced survival of tumor-bearing mice.

229 ances the overall survival of the respective tumor-bearing mice.

230 delivery and increased the survival of brain tumor-bearing mice.

231 sorted immune T cells derived from naive and tumor-bearing mice.

232 though tumor development is delayed in E0771 tumor-bearing mice.

233 uced adipose and muscle mass and function in tumor-bearing mice.

234 stasis and extended the survival of systemic tumor-bearing mice.

235 imaging and biodistribution studies in LNCaP tumor-bearing mice.

236 largement and reduced coupling efficiency in tumor-bearing mice.

237 hibitor, olaparib, and prolonged survival in tumor-bearing mice.

238 s cDC1 apoptosis, rescuing cDC1 abundance in tumor-bearing mice.

239 imaging and biodistribution studies in LNCaP tumor-bearing mice.

240 ed tumor burden and extended the lifespan of tumor-bearing mice.

241 h nodes, and increasing IL-2 in the serum of tumor-bearing mice.

242 f XBP1 causes skeletal muscle wasting in LLC tumor-bearing mice.

243 -HB-to-[1-(13)C]AcAc ratios were observed in tumor-bearing mice.

244 -(13)C(2)]beta-HB was detected in normal and tumor-bearing mice.

245 was evaluated by systemic administration to tumor-bearing mice.

246 temperature remained elevated, comparable to tumor-bearing mice.

247 and its ratio to CD8(+) T cells increased in tumor-bearing mice.

248 In a non-tumor bearing mouse model, the Provector demonstrates ef

249 TMZ treatment in the non-tumor bearing mouse-model diminished the F/B ratio, incr

250 In a tumor-bearing mouse injected with 3 MBq of [(213)Bi-DOTA

251 imaging and biodistribution studies, a C4-2 tumor-bearing mouse model was used.

252 "exposed" surface labeled variants in a CT26 tumor-bearing mouse model.

253 and image the endogenous NQO1 in three live tumor-bearing mouse models (A549 lung cancer, Lewis lung

254 bination was further confirmed by using PC-3 tumor-bearing mouse models.

255 it tumor growth as well as metastasis in the tumor-bearing mouse models.

256 inally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed.

257 of gold nanoparticles (GNPs) injected into a tumor-bearing mouse.

258 aterials and Methods A total of 21 VX2 liver tumor-bearing New Zealand white rabbits were used betwee

259 GSI treatment of MM tumor-bearing NOD/SCID/gammac-/- mice increased BCMA exp

260 tween the two and for selective resection of tumor-bearing nodes using Cerenkov imaging.

261 ion, and survival in C4-2 or C4-2 TP53 (-/-) tumor-bearing nonobese diabetic scid gamma-mice.

262 r systemic administration into orthotopic MB tumor bearing NSG mice compared to non-targeted JQ1 load

263 dose of 20 mg/kg into orthotopic pancreatic tumor-bearing NSG mice every alternate day resulted in s

264 We have shown that the non-tumor-bearing (NT), recombinant adeno-associated virus (

265 all-animal PET experiments were performed on tumor-bearing nude mice after subcutaneous injection of

266 so evaluated in HCC827, H1975, H358 and H520 tumor-bearing nude mice by PET/CT imaging.

267 lencing, to loss of ARF function, as well as tumors bearing oncogenic NF-kappaB activation.

268 y to measure the stiffness of healthy versus tumor-bearing optic nerve tissue.

269 average elastic moduli of non-neoplastic and tumor-bearing optic nerves were approximately 3 and appr

270 Tumor-bearing organs were processed by using tissue clea

271 group, that were significantly decreased in tumor-bearing preparations.

272 nistration of into hepatic arteries of a VX2 tumor-bearing rabbit under fluoroscopy, followed by subs

273 Fifteen VX2-tumor-bearing rabbits were assigned to three groups depe

274 injections of rat hepatoma cells (H4IIE); 24 tumor-bearing rats (mean tumor diameter, approximately 1

275 (dox) and [Gd(HPDO3A)(H2O)], and injected in tumor-bearing rats before MR-HIFU treatment.

276 13)C]glycine SNR was significantly higher in tumor-bearing rats compared to controls, and in tumor re

277 Comparison of control and tumor-bearing rats showed no difference in gamma-glutamy

278 enables assessment of ERbeta availability in tumor-bearing rats.

279 sue obtained from breast cancer patients and tumor-bearing rats.

280 (18)F-hGTS13-isomer2 were evaluated in H460 tumor-bearing rats.

281 red from DGKzeta-deficient mice to wild-type tumor-bearing recipients conferred this benefit.

282 ium-2G11 mAb was performed in 143B and OS-17 tumor-bearing SCID mice and followed by radioimmunothera

283 = 7) and control groups (n = 6-7) using C4-2 tumor-bearing SCID mice by evaluating tumor growth and s

284 functional capacity of PD-1(hi) CD8 TILs in tumor-bearing sepsis survivors, checkpoint blockade ther

285 and (177)Lu-PSMA I&T was determined in LNCaP tumor-bearing severe combined immunodeficiency (SCID) mi

286 in PD-L1-positive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

287 ated in GATA3 mutant cells in culture and in tumors bearing similar mutations in vivo.

288 Imaging was performed in tumor-bearing Smo/Smo medulloblastoma mice with constitu

289 ify transcriptional programs associated with tumors bearing specific genetic driver alterations.

290 epletion of CD4(+) but not CD8(+) T cells in tumor-bearing subjects reversed the inhibitory effects o

291 outcomes elicited by bacterial infections in tumor-bearing subjects.

292 ed with 2 x 10(7) of Walker 256 tumor cells [tumor bearing (TB) rats].

293 tumor, and how the profile compares with non-tumor-bearing tissues.

294 Critically, LLC tumor-bearing TLR4(-/-) mice were spared from muscle was

295 ro and accelerated metastatic progression in tumor-bearing TRAMP mice.

296 titumor effector cells when transferred into tumor-bearing untrained animals.

297 a, PMNs were recruited less intensely to the tumor-bearing uterus, but the recruited cells much more

298 Tumor bearing was positively correlated with the osteocl

299 In PC-3 tumor-bearing xenograft mice, the CC-trapping, GRPR-targ

300 HCC1954 tumor-bearing xenograft models were established, and (18